Business Wire

NY-REVIV

1.3.2024 13:36:33 CET | Business Wire | Press release

Share
Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV

The DRIPBaR, recognized as the fastest-growing IV therapy franchise in the United States, has joined forces with REVIV, the global leader in IV therapy, marking a significant milestone for the industry. The partnership creates an unrivaled offering by bringing together the specialties of two industry heavyweights boasting over 200 locations across 6 continents, with plans to add thousands more locations in the coming years. The recent surge in demand for IV therapy presents enormous opportunities globally for the companies to redefine industry standards and spearhead the next era of IV therapy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301173923/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ben Crosbie, CEO of The DRIPBaR and Sarah Lomas, Founder and CEO of REVIV Global, announce their exciting partnership. (Photo: Business Wire)

With an extensive pipeline boasting over 450 franchisees in the United States, The DRIPBaR's decision to integrate REVIV's proprietary technology-backed proposition, REVIV X, validates their commitment to provide personalized and precision nutrition solutions for their customers. This partnership empowers The DRIPBaR to leverage REVIV's 10 years of intellectual property and life science expertise, utilizing objective data from blood tests and DNA analysis to tailor IV therapies to individual needs. Through REVIV X, The DRIPBaR is poised to revolutionize the wellness landscape in the United States, offering patient-focused solutions that optimize health outcomes that will solidify its position as a leader in innovation.

Ben Crosbie, CEO of The DRIPBaR, expressed excitement in the collaboration, affirming, "By selecting REVIV as our strategic partner, we are unlocking personalized and precision capabilities for a more advanced product offering and customer experience. I’m very confident that leveraging REVIV's cutting-edge technology and expertise will accelerate the growth of our franchisees and position them ahead of industry norms. The REVIV X proposition, coupled with its accredited IV Academy training course, sets a global benchmark for excellence in our field, empowering us to maintain industry leadership."

Sarah Lomas, Founder and CEO of REVIV Global, highlighted the transformative impact of the partnership, stating, "The DRIPBaR's alignment with REVIV underscores our joint dedication to innovation and safety in the IV therapy market. As industry leaders, we are reshaping the future of wellness by offering personalized and precision nutrition solutions that cater to evolving customer needs. We will continue to develop our SaaS products to power the industry globally. After many years and significant investment in research and product development, it’s exciting to see such early validation and adoption for REVIV X."

This strategic alliance between REVIV and The DRIPBaR marks a pivotal moment in the IV therapy industry and multi-modality sectors, advancing the delivery of safe, effective, and tailored wellness solutions to customers across the United States and beyond. As the IV therapy market continues its rapid expansion, with safety and compliance at the forefront, REVIV X emerges as the solution of choice for IV therapy operators, creating the opportunity for existing multi-modality businesses to access REVIV's innovative solutions and maintain their position at the forefront of wellness innovation and industry standards.

About REVIV Global

REVIV Global is at the forefront of advanced wellness solutions, devoted to enriching health and vitality through state-of-the-art IV therapy treatments. With a widespread international footprint and a relentless pursuit of innovation, REVIV is spearheading a revolution in the wellness sector. Its distinctive technological platform empowers IV therapy providers to deliver personalized and precision solutions with unparalleled safety and efficiency.

About The DRIPBaR

The DRIPBaR, a pioneering brand in the realm of wellness, is poised to redefine the landscape of health and vitality through advances in IV therapy. With cutting-edge science and a strong commitment to safety, The DRIPBaR offers a transformative approach to cellular health and personalized care. Focusing on ever-evolving treatments and medical advancements, The DRIPBaR embraces a new era of wellness where rejuvenation, vitality, and optimized health converge.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240301173923/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release

Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh

Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release

Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye